You are here:
Direct Healthcare Professional Communication (DHPC) on Cabazitaxel Accord® 20 mg/ml concentrate for solution for infusion: risk of medication errors and confusion with Jevtana® (60 mg/1.5 ml) concentrate and solvent for solution for infusion
2021.03.09
Active substance: cabazitaxel
Accord Healthcare S.L.U., Spain in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform about the risk of medication errors due to the presence on the market of different cabazitaxel presentations. A mix-up between the products may lead to either overdosing with potentially fatal outcome, or underdosing with reduction of therapeutic effect (see background section below).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN